Trovagene Q3 Revenues Decline | GenomeWeb

NEW YORK (GenomeWeb News) – Trovagene reported after the close of the market Thursday that its third quarter revenues fell to $44,000 from $211,000 year over year.

All of the firm's revenues were derived from royalties, a company official said on a conference call following the release of the results.

Trovagene posted a net loss of $4.4 million, or $.25 per share, for the three month period ended Sept. 30, compared to a net loss of $660,000, or $.05 per share, for Q3 2012.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: researchers explore the transfer of host genetic material into viruses, and more.

It's too difficult to correct or retract a flawed scientific paper, researchers write in Nature.

A proposed bill would require NSF to only fund research that's in "the national interest."

Australia's Commonwealth Scientific and Industrial Research Organisation plans to eliminate up to 350 jobs.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.